<DOC>
	<DOC>NCT01531322</DOC>
	<brief_summary>This study will assess the safety and tolerability of a single dose of 13-valent Pneumococcal Conjugate Vaccine for approximately 1 month after vaccination sequentially in healthy Chinese adults aged 18 through 55 years, followed by children aged 3 through 5 years, and then infants aged approximately 2 months.</brief_summary>
	<brief_title>A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>1. Age at the time of enrollment is: 18 through 55 years (before the fifty sixth birthday) for Group 1. 3 through 5 years (before the sixth birthday) for Group 2. 42 to 98 days for Group 3. 2. Healthy subject as determined by medical history, physical examination, and judgment of the investigator. Previous vaccination with licensed or investigational pneumococcal vaccine. Previous anaphylactic reaction to any vaccine or vaccinerelated component. Contraindication to vaccination with pneumococcal vaccine.</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>13vPnC</keyword>
	<keyword>Healthy subjects</keyword>
	<keyword>China</keyword>
</DOC>